Endovastec™ announced that its Talos™ Thoracic Stent Graft System (Talos™) has recently received marketing approval in Brazil and Argentina, marking an important milestone in the company’s global strategy and its commitment to improving patient access to advanced aortic therapies. 

Talos™ is a next-generation straight thoracic stent graft system, and the world’s first “breathing” stent graft specifically designed for the treatment of Stanford type B aortic dissection. It can improve the reshaping of the distal true lumen by extending the stent length. Its unique distal honeycomb design (length can be selected from 0 mm to 200 mm) can enlarge the distal true lumen diameter of the thoracic aorta, reduce the possibility of spinal cord ischemia caused by overlying intercostal arteries, and improve the long-term treatment outcomes. With a maximum stent length of 260 mm, Talos™ is designed to optimize aortic remodeling outcomes in complex cases.

Latin America represents a key region in Endovastec™’s global footprint. The company’s aortic product portfolio is already in clinical use across several countries in this region, including Brazil, Argentina, Colombia, and Mexico. The approval of Talos™ in Brazil and Argentina will further reinforce the company’s regional presence and broadens the range of innovative treatment options available to patients with aortic disease.